Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Era in Cancer Diagnostics

Published: Tuesday, June 04, 2013
Last Updated: Tuesday, June 04, 2013
Bookmark and Share
Novel development for improved cancer diagnosis and treatment monitoring.

A new generation of cancer diagnostic devices has been unveiled by Singapore-based Clearbridge BioMedics, following its work with product development firm Cambridge Consultants.

The new ClearCell FX System is designed to improve cancer diagnosis and treatment monitoring by allowing doctors to rapidly isolate circulating tumour cells (CTCs) in a patient’s bloodstream - paving the way for more personalized medicine.

The ClearCell FX System separates and isolates cells in a patient’s blood sample using novel inertia focusing spiral microfluidics in the single-use CTChip FR. This allows for continuous label-free separation - i.e. without biochemical labels - of CTCs from blood cells.

The larger and denser CTCs are separated from the other blood cells within the spiral biochip due to biomechanical differences - and are then focused into an enriched cell ‘stream’.

These cell streams are channeled and collected into an enriched sample, which can be used for pathology diagnostic tests such as mutation testing for targeted therapies.

John Pritchard, head of diagnostics at Cambridge Consultants, said: “This has been a collaborative merging of our extensive experience in diagnostic device development and Clearbridge BioMedics’ expertise in cancer research and diagnostics - and it’s led to breakthrough technology that will have a huge impact on a lot of people’s lives. Our systems engineering approach, coupled with our skills in fluidics, software and compliance, has enabled us to work quickly and efficiently with Clearbridge BioMedics - even though we are thousands of miles apart.”

Clearbridge BioMedics also worked in collaboration with the National University of Singapore and the Singapore-MIT Alliance for Research and Technology (SMART) Center.

The new system - which has been designed for both research and diagnostics applications - will be undergoing regulatory approval in the US and Europe.

Johnson Chen, co-founder and managing director of Clearbridge BioMedics, said: “Once approved, it will be one of the world’s first label-free CTC enrichment systems for diagnostic use. Clearbridge BioMedics believes this system will be an ideal companion diagnostic system that complements various cancer therapies.”

Set up in late 2009, Clearbridge BioMedics is a spin-off company from the National University of Singapore. The firm’s first-generation ClearCell System - which was launched for the cancer research market in 2011 - was one of the first non-biomarker-based systems commercially available to detect, isolate and retrieve CTCs from blood.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!